Pan-Canadian Pharmaceutical Alliance Lacks Transparency and Accountability: Nigel Rawson for Inside Policy
Negotiations to limit drug prices should not limit patients’ access to innovative drugs, writes Nigel Rawson. By Nigel Rawson, February ...
Negotiations to limit drug prices should not limit patients’ access to innovative drugs, writes Nigel Rawson. By Nigel Rawson, February ...
The CPP experience shows that we must also put forward constructive alternatives that respond to the needs of those poorly-served ...
With the federal government toying with a national pharmacare plan, MLI Munk Senior Fellow Sean Speer spoke at a panel ...
A federal intrusion that disrupts coverage for three quarters of the population, requires tax hikes and spending cuts, and leads ...
Canadians don’t tend to think much about the federal Department of Health and its role in Canadian health care. How ...
Phamacare reform should be surgical and targeted rather than transformative, writes Sean Speer. By Sean Speer, September 28, 2018 There’s ...
The federal government’s possible foray into pharmacare would represent an unprecedented expansion of Ottawa’s role in Canadian health care, writes ...
Instead of a one-size-fits-all government pharmacare model, we should focus on targeted, incremental reforms of the current system, writes Sean ...
Adopting single-payer coverage is not the solution to the challenges facing Canada’s pharmacare system, writes Sean Speer. By Sean Speer, ...
The federal government is proposing dramatic changes to the pricing of new patented medicines in Canada, and it announced in ...
323 Chapel Street, Suite #300
Ottawa, Ontario
K1N 7Z2 Canada
613.482.8327
Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.
© 2021 Macdonald-Laurier Institute. All Rights reserved.